962 related articles for article (PubMed ID: 16226919)
21. Safety and efficacy of gene transfer for Leber's congenital amaurosis.
Maguire AM; Simonelli F; Pierce EA; Pugh EN; Mingozzi F; Bennicelli J; Banfi S; Marshall KA; Testa F; Surace EM; Rossi S; Lyubarsky A; Arruda VR; Konkle B; Stone E; Sun J; Jacobs J; Dell'Osso L; Hertle R; Ma JX; Redmond TM; Zhu X; Hauck B; Zelenaia O; Shindler KS; Maguire MG; Wright JF; Volpe NJ; McDonnell JW; Auricchio A; High KA; Bennett J
N Engl J Med; 2008 May; 358(21):2240-8. PubMed ID: 18441370
[TBL] [Abstract][Full Text] [Related]
22. The Consequences of Hypomorphic RPE65 for Rod and Cone Photoreceptors.
Samardzija M; Barben M; Geiger P; Grimm C
Adv Exp Med Biol; 2016; 854():341-6. PubMed ID: 26427430
[TBL] [Abstract][Full Text] [Related]
23. Bax-induced apoptosis in Leber's congenital amaurosis: a dual role in rod and cone degeneration.
Hamann S; Schorderet DF; Cottet S
PLoS One; 2009 Aug; 4(8):e6616. PubMed ID: 19672311
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis.
Pang JJ; Chang B; Kumar A; Nusinowitz S; Noorwez SM; Li J; Rani A; Foster TC; Chiodo VA; Doyle T; Li H; Malhotra R; Teusner JT; McDowell JH; Min SH; Li Q; Kaushal S; Hauswirth WW
Mol Ther; 2006 Mar; 13(3):565-72. PubMed ID: 16223604
[TBL] [Abstract][Full Text] [Related]
25. Effect of gene therapy on visual function in Leber's congenital amaurosis.
Bainbridge JW; Smith AJ; Barker SS; Robbie S; Henderson R; Balaggan K; Viswanathan A; Holder GE; Stockman A; Tyler N; Petersen-Jones S; Bhattacharya SS; Thrasher AJ; Fitzke FW; Carter BJ; Rubin GS; Moore AT; Ali RR
N Engl J Med; 2008 May; 358(21):2231-9. PubMed ID: 18441371
[TBL] [Abstract][Full Text] [Related]
26. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal chromophore injections delay early-onset and rapid retinal cone degeneration in a mouse model of Leber congenital amaurosis.
Dai X; Jin X; Ye Q; Huang H; Duo L; Lu C; Bao J; Chen H
Exp Eye Res; 2021 Nov; 212():108776. PubMed ID: 34582935
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.
Li S; Samardzija M; Yang Z; Grimm C; Jin M
J Neurosci; 2016 May; 36(21):5808-19. PubMed ID: 27225770
[TBL] [Abstract][Full Text] [Related]
29. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection.
Jacobson SG; Acland GM; Aguirre GD; Aleman TS; Schwartz SB; Cideciyan AV; Zeiss CJ; Komaromy AM; Kaushal S; Roman AJ; Windsor EA; Sumaroka A; Pearce-Kelling SE; Conlon TJ; Chiodo VA; Boye SL; Flotte TR; Maguire AM; Bennett J; Hauswirth WW
Mol Ther; 2006 Jun; 13(6):1074-84. PubMed ID: 16644289
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.
Gardiner KL; Cideciyan AV; Swider M; Dufour VL; Sumaroka A; Komáromy AM; Hauswirth WW; Iwabe S; Jacobson SG; Beltran WA; Aguirre GD
Mol Ther; 2020 Jan; 28(1):266-278. PubMed ID: 31604676
[TBL] [Abstract][Full Text] [Related]
32. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA.
Jacobs JB; Dell'Osso LF; Wang ZI; Acland GM; Bennett J
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4685-92. PubMed ID: 19458334
[TBL] [Abstract][Full Text] [Related]
33. Early-Onset Progressive Degeneration of the Area Centralis in RPE65-Deficient Dogs.
Mowat FM; Gervais KJ; Occelli LM; Annear MJ; Querubin J; Bainbridge JW; Smith AJ; Ali RR; Petersen-Jones SM
Invest Ophthalmol Vis Sci; 2017 Jun; 58(7):3268-3277. PubMed ID: 28662231
[TBL] [Abstract][Full Text] [Related]
34. AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.
Boye SL; Peshenko IV; Huang WC; Min SH; McDoom I; Kay CN; Liu X; Dyka FM; Foster TC; Umino Y; Karan S; Jacobson SG; Baehr W; Dizhoor A; Hauswirth WW; Boye SE
Hum Gene Ther; 2013 Feb; 24(2):189-202. PubMed ID: 23210611
[TBL] [Abstract][Full Text] [Related]
35. Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina.
Bainbridge JW; Mistry A; Schlichtenbrede FC; Smith A; Broderick C; De Alwis M; Georgiadis A; Taylor PM; Squires M; Sethi C; Charteris D; Thrasher AJ; Sargan D; Ali RR
Gene Ther; 2003 Aug; 10(16):1336-44. PubMed ID: 12883530
[TBL] [Abstract][Full Text] [Related]
36. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
[TBL] [Abstract][Full Text] [Related]
37. Nrl-knockout mice deficient in Rpe65 fail to synthesize 11-cis retinal and cone outer segments.
Feathers KL; Lyubarsky AL; Khan NW; Teofilo K; Swaroop A; Williams DS; Pugh EN; Thompson DA
Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1126-35. PubMed ID: 18326740
[TBL] [Abstract][Full Text] [Related]
38. Protection of cone photoreceptor M-opsin degradation with 9-cis-β-carotene-rich alga Dunaliella bardawil in Rpe65(-/-) mouse retinal explant culture.
Ozaki T; Nakazawa M; Kudo T; Hirano S; Suzuki K; Ishiguro S
Curr Eye Res; 2014 Dec; 39(12):1221-31. PubMed ID: 25006880
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function.
Annear MJ; Bartoe JT; Barker SE; Smith AJ; Curran PG; Bainbridge JW; Ali RR; Petersen-Jones SM
Gene Ther; 2011 Jan; 18(1):53-61. PubMed ID: 20703309
[TBL] [Abstract][Full Text] [Related]
40. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
Pierce EA; Bennett J
Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
